HNSCC

This study tests an experimental drug called YL202 in about 200 people with advanced solid tumors, including lung, breast, and head & neck cancers. The goal is to see if the drug can shrink tumors and how safe it is. Participants must be between 18 and 75 years old and have tried…

This early-phase study tests a new drug, VLPONC-01, injected directly into head and neck tumors to see if it's safe and can shrink tumors. About 41 adults with advanced head and neck cancer will receive the injection alone or with an immunotherapy drug (pembrolizumab). The goal i…

This early-phase study is testing whether two experimental drugs, finotonlimab and stapokibart, are safe and can shrink tumors in people with advanced head and neck cancer that has come back or spread. The study will include 10 adults whose cancer got worse after standard treatme…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This early-phase study tests a new drug called DCSZ11 alongside standard treatments in 9 adults with advanced or metastatic solid tumors, including head and neck cancer. The goal is to see if the combination is safe and helps shrink or control tumors. Participants must have stand…

This study tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, and colorectal cancers. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants receive the drug every 3 weeks and are closely monitored…

This early-phase study tests a new drug called 177Lu-RAD204, which is a radioactive antibody that seeks out and attaches to a protein (PD-L1) on cancer cells. The goal is to see if it is safe and tolerable for people with advanced solid tumors like lung, breast, or skin cancer th…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This early-stage study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head and neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also measure drug levels in the blood…

This early-phase study tests a new drug called ALX2004 in people with advanced or metastatic solid tumors (lung, head and neck, colorectal, esophageal) that have not responded to standard treatments. ALX2004 is an antibody drug conjugate designed to deliver chemotherapy directly …

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This study is testing a new drug, enzelkitug, for people with advanced solid tumors that have spread or cannot be removed by surgery. The trial includes many cancer types like lung, head and neck, melanoma, breast, and others. The main goal is to check the drug's safety and find …

This early-stage trial tests a new drug called GV20-0251 in people with advanced solid tumors that no longer respond to standard treatments. The main goal is to check the drug's safety. About 10 adults with cancers like liver, lung, or skin cancer will take part. This is not a cu…

This study tests a new drug (HCB101) combined with an existing immunotherapy (pembrolizumab) for people with advanced head and neck cancer that no longer responds to platinum chemotherapy. About 50 adults will receive the combination to see if it is safe and can shrink tumors or …

This early-phase study tests a new drug called NRM-823, alone or with an immunotherapy, in 150 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. The study includes several cancer types lik…

This early study tests a new treatment for people with advanced head and neck cancer that has come back or spread. The treatment uses a patient's own immune cells (called TILs) that are grown in a lab and given back along with a drug that helps them attack the cancer. The main go…

This early-phase study is testing whether adding two immunotherapy drugs (cemiplimab and cetuximab) to standard chemotherapy before surgery is safe and effective for people with advanced head and neck cancer. The goal is to see if this approach might allow patients to skip radiat…

This early-stage study tests a new injection called TI-0093 in 12 adults with HPV-16 positive cancers (like head, neck, or cervical cancer) that returned or spread. The main goals are to check safety, find the best dose, and see how the body responds. It is not a cure but aims to…

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This study tests a new, high-resolution PET-CT scanner that takes detailed pictures of a tumor right after it is removed during surgery. The goal is to help surgeons see if any cancer cells are left behind, so they can remove more tissue if needed. About 50 adults with solid tumo…

This early-phase study tests a fluorescent dye attached to the cancer drug panitumumab to make head and neck cancer cells glow during surgery. About 18 adults with head and neck cancer who are already scheduled for surgery will receive the dye infusion before their operation. The…

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already scheduled to receive immunotherapy (PD-1/PD-L1 inhibitors). Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if chan…